Brizzey provides consulting services, training, tool design, selection and implementation, process modeling and project management. We pride ourselves on offering services that are good value, collaborative, supportive, focused, balanced and practical, in order to help organizations get to the next level.
We have 70+ years combined experience in various aspects of R&D Supply Chain Management, Quality Assurance, Process Optimization, and Organizational Change. We have 17+ years working together on R&D supply chain roles and founded Brizzey in 2014. |
We’ve delivered over 60 projects for 37 clients, including 29 sponsors, 4 CMOs and 4 consultant groups.
We have access to partners experienced in:
|
Brizzey collaborates with a network of selected Partner Organizations to provide drug development services that our clients need but that fall outside the scope of our internal expertise.
|
These established, long-term partnerships are designed to facilitate seamless execution of your project. Together, we will work with these trusted, highly skilled partners to drive your program to success.
|
Ultramikro, LLC is a consultant firm providing guidance for pharmaceutical and food industries in contamination control and in global pharmacopeial compliance. Particulate matter in the pharmaceutical presentation may be foreign material or may form due to substances intrinsic to the formulation or package. Removing the sub-visible (—less than 100μm) and larger particles or reducing their impact is quite dependent upon their identification, which is facilitated through analysis by a variety of instruments and approaches. Microscopical applications are foremost in the Ultramikro approach.
|
The collaboration between Brizzey and Ultramikro ensures that the skills necessary to solve unexpected challenges during product development are available when needed. |
Mark VanArendonk founded Vermeer Pharma, LLC in 2018. He has more than 30 years of pharmaceutical experience and specializes in CMC drug development. During his “big pharma” career, Mark held positions of increasing responsibility in Analytical R&D, Quality Assurance and CMC at various companies, concluding as Merck Vice President for Analytical Chemistry in Development and Supply, where he was responsible for late stage development programs from IIB through registration, launch and commercialization.
As an independent consultant, Dr. VanArendonk supports small and medium-sized companies in early and late development. |
We believe that the partnership between Brizzey and Vermeer Pharma brings together a dynamic combination of skills and experience which will facilitate our clients’ pathway to end-to-end development and increase the rate at which they can bring medicines to patients. |
Crux Move Consulting is an accomplished organizational development firm, specializing in organizational culture change and helping build effective leaders, teams and organizations through experiential learning. Crux Move is available to help get your people working together effectively and aligned with your business goals. Using powerful, tried and tested leadership and team development processes, they will help you meet your culture change goals, whether you are looking to enhance the culture of your leadership team or change the culture of your entire organization.
|
The collaboration between Brizzey and Crux Move is designed to bring together an unprecedented combination of skills and experience to holistically address the people, partnership and processes of your organizational change initiatives. |
Synergy Partners R&D Solutions is a network of scientists with a depth of experience in all aspects of pharmaceutical research and development, from target selection to clinical proof of concept and beyond. They have a track record of turning exciting discoveries into medicines, by partnering with clients to design and implement the optimal development strategy for each molecule. Synergy is available to support you in all aspects of drug discovery and development, including biology, pharmacology, chemistry, drug safety, DMPK, clinical and regulatory. Synergy will work with your team to design and oversee the execution of appropriate testing and integrate the knowledge gained into downstream plans, to position your program for a seamless transition to development.
|
The collaboration between Brizzey and Synergy Partners is designed to bring a breadth of expertise to your research and development programs, while offering a seamless transition from research into development. |
John Skoug founded FarmCMC in 2019 in order to leverage his technical and leadership expertise to help small and medium sized biopharmaceutical companies develop novel therapeutic assets and delivery systems through both early and late stages.
John has more than 30 years of pharmaceutical industry experience and specializes in CMC product development across all stages of discovery and development. Prior to founding Farm CMC, he was Senior Director in AbbVie’s drug product R&D organization. There, he held a number of roles, in which he was responsible for CMC technical strategy and execution for small molecule programs and combination product programs for biologics. John brings a unique breadth of CMC experience, including pharmaceutics support of discovery teams as well as drug and device delivery system technology assessment. |
Together, Brizzey and FarmCMC offer a complementary set of skills and experience, which can help clients with a broad range of activities essential to development of novel therapeutic assets and delivery systems. |